US Diabetes Devices Market - 2025-2033

The US diabetes devices market reached US$ 10.25 billion in 2024 and is expected to reach US$ 18.93 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033.

Diabetes devices are medical instruments or equipment used to help individuals with diabetes manage and monitor their condition. These devices are essential for tracking blood glucose levels, administering insulin, and preventing complications associated with diabetes. The primary goal of these devices is to provide better control over blood sugar levels, enhance overall diabetes management, and improve quality of life. Continuous glucose monitors are ideal for people who need constant glucose monitoring, offering data about trends and fluctuations that can help optimize diabetes management and they can alert users to high or low glucose levels, helping to prevent hypoglycemia or hyperglycemia.

Market Dynamics: Drivers & Restraints

Rising advancements in diabetes technology

The rising advancements in diabetes technology are significantly driving the growth of the diabetes devices market and are expected to drive the market over the forecast period. Continuous glucose monitoring systems provide real-time, continuous tracking of glucose levels, allowing for more proactive management of blood sugar. Unlike traditional glucose meters that require finger pricks, CGMs provide data 24/7, alerting users to high or low glucose levels and improving glycemic control.

Thus, major market players in the United States are focusing on the advancements and affordability of CGMs. For instance, in August 2024, Dexcom announced that its over-the-counter continuous glucose monitor Stelo is available for use in the United States. The device available at a price of $99 for a pack of two sensors, which could be used for up to 30 days. The U.S. Food and Drug Administration cleared the use of the device, making it the first continuous glucose monitor to be available without a prescription.

Insulin pumps have evolved into automated insulin delivery systems that integrate with CGMs for closed-loop systems (artificial pancreas). These systems automatically adjust insulin doses based on real-time glucose readings, significantly reducing the need for manual insulin adjustments and minimizing human error. For instance, Medtronic and Tandem Diabetes are major players in this field, with devices like the Medtronic MiniMed 670G and Tandem t:slim X2, both featuring automated insulin adjustments. The integration of AI and machine learning into these devices allows for even more precise insulin delivery.

High cost of the devices

The high cost of diabetes devices is a significant barrier to the growth of the US diabetes devices market, as it limits accessibility and affordability for many patients. Although advanced diabetes management technologies like continuous glucose monitors (CGMs), insulin pumps and smart insulin pens offer improved outcomes, their high prices create financial challenges for both individuals and healthcare systems. For instance, according to the National Institute of Health, the costs of CGM are substantially offset if device costs are added, with an average of $4,431 during the 12-month follow-up versus $319 for a blood glucose monitor.

Devices such as Continuous Glucose Monitors (CGMs), insulin pumps and closed-loop systems tend to have high costs, making them out of reach for many diabetes patients. For instance, a Dexcom G6 transmitter costs $366 without insurance for one device that lasts 90 days. The Dexcom G6 CGM system can cost around $8,000 annually out-of-pocket, excluding a receiver for non-smartphone users ($540) and a compatible phone. The high cost limits the adoption of CGM systems, particularly in low- and middle-income countries. This high price is a major barrier to the widespread use of CGMs and insulin pumps.

Segment Analysis

The US diabetes devices market is segmented based on product type and end-user.

Product Type:

The blood glucose monitoring devices in the product type segment are expected to dominate the US diabetes devices market with the highest market share.

The prevalence of diabetes in the United States is high, more than 38 million Americans have diabetes. This creates a large market for blood glucose monitoring devices, as regular glucose monitoring is a critical part of managing both Type 1 and Type 2 diabetes. Diabetes requires frequent blood sugar testing to ensure that glucose levels remain within a healthy range. While insulin pumps are gaining popularity, continuous glucose monitoring devices and self-monitoring devices are still the most commonly used and cost-effective tools for daily monitoring. Thus, major players in the United States are developing the CGMs with advanced features.

For instance, in June 2024, Prevounce Health launched its first remote blood glucose monitoring device, Pylo GL1-LTE. The blood glucose meter is clinically validated and connects to multiple cellular networks to better ensure reliable data transmission throughout the United States. The GL1-LTE is available for use with the Prevounce remote care management platform and can integrate with other health software via the Pylo cloud API. Prevounce's line of Pylo cellular-connected devices also includes blood pressure monitors and weight scales.

Competitive Landscape

The major US players in the diabetes devices market include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Medtronic plc, Terumo Corporation, B. Braun SE, Insulet Corporation, Nipro Corporation, Johnson & Johnson Services, Inc., Senseonics, Inc., Tandem Diabetes Care, Inc. and among others.

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The US diabetes devices market report delivers a detailed analysis with 36 key tables, more than 23 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.